Page 76 - Read Online

Page 10 of 10 Tãtaru et al. Rare Dis Orphan Drugs J 2024;3:19 https://dx.doi.org/10.20517/rdodj.2024.08

2023;182:2935-42. DOI PubMed PMC
15. Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets
for personalized medicine. Cell Rep Med 2021;2:100346. DOI PubMed PMC
16. Wilson JMG, Jungner G. Principles and practice of screening for disease. 1968. Available from: https://niercheck.nl/wp-content/
uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 6 Jun 2024].
17. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler
PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-68.
DOI PubMed PMC
18. Cances C, Vlodavets D, Comi GP, et al. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study.
Orphanet J Rare Dis 2022;17:300. DOI PubMed PMC
19. Annoussamy M, Seferian AM, Daron A, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann
Clin Transl Neurol 2021;8:359-73. DOI
20. Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new
implications for care. J Neuromuscul Dis 2020;7:1-13. DOI PubMed PMC
21. Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular
atrophy and economic evaluations of treatments. Orphanet J Rare Dis 2021;16:47. DOI PubMed PMC
22. SMA NBS Alliance. Spinal muscular atrophy: screen at birth, save lives. 2021. Available from: http://www.eamda.eu/wp-content/
uploads/2021/05/Spinal_muscular_atrophy_Screen_at_birth_save_lives_Whitepaper_SMA_NBS_Alliance_v1_26March21.pdf [Last
accessed on 6 Jun 2024].
23. Morbidity and Mortality Weekly Report. CDC grand rounds: newborn screening and improved outcomes. 2012. Available from:
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a2.htm [Last accessed on 6 Jun 2024].
24. IQWIG-Bericht - Nr. 891. Neugeborenenscreening auf 5q-assoziierte spinale Muskelatrophie. Available from: https://www.iqwig.de/
download/s18-02_neugeborenenscreening-auf-5q-assoziierte-sma_abschlussbericht_v1-0.pdf [Last accessed on 6 Jun 2024].
25. Boemer F, Caberg JH, Dideberg V, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 2019;29:343-9.
DOI
26. Chen X, Sanchis-Juan A, French CE, et al. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data.
Genet Med 2020;22:945-53. DOI PubMed PMC
27. WEBINAR. Newborn screening techniques for SMA. Available from: https://www.youtube.com/watch?v=Jh0iJLL_7Hs [Last
accessed on 6 Jun 2024].
28. EURORDIS Rare Diseases Europe. Available from: https://www.eurordis.org/rare-barometer/english/ [Last accessed on 6 Jun 2024].
29. Rare disease patients’ opinion on the future of rare diseases: a rare barometer survey for the rare 2030 foresight study. Available from:
https://download2.eurordis.org/rbv/rare2030survey/reports/RARE2030_survey_public_report_en.pdf [Last accessed on 6 Jun 2024].
30. Global leaders convene in London: advancing newborn sequencing on an international scale. 2023. Available from: https://
genomes2people.medium.com/global-leaders-convene-in-london-advancing-newborn-sequencing-on-an-international-scale-
590c8af350d7 [Last accessed on 6 Jun 2024].
31. ICoNS. Available from: https://www.iconseq.org/publications [Last accessed on 6 Jun 2024].
32. Newborn screening: toward a uniform screening panel and system. Available from: https://www.hrsa.gov/sites/default/files/hrsa/
advisory-committees/heritable-disorders/newborn-uniform-screening-panel.pdf [Last accessed on 6 Jun 2024].
33. Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in
England. Neurol Ther 2023;12:1205-20. DOI PubMed PMC
34. Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for
spinal muscular atrophy in The Netherlands. Value Health 2022;25:1696-704. DOI PubMed
35. Dangouloff T, Thokala P, Stevenson MD, et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world
data in Belgium. Neuromuscul Disord 2024;34:61-7. DOI
36. Liu G, Lipari P, Mollin A, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and
vamorolone in DMD disease models. Hum Mol Genet 2024;33:211-23. DOI PubMed PMC
37. Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal
disease. 2018. Available from: https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-
gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease [Last accessed on 6 Jun 2024].
38. World Health Organization. Standards for improving the quality of care for small and sick newborns in health facilities. Available
from: https://iris.who.int/bitstream/handle/10665/334126/9789240010765-eng.pdf?sequence=1 [Last accessed on 6 Jun 2024].
39. EURORDIS Rare Diseases Europe. Key principles for newborn screening. Available from: https://download2.eurordis.org/documents/
pdf/eurordis_nbs_position_paper.pdf [Last accessed on 6 Jun 2024].
40. Health Resources & Services Administration. Recommended uniform screening panel. Available from: https://www.hrsa.gov/
advisory-committees/heritable-disorders/rusp [Last accessed on 6 Jun 2024].